Stockscreener 앱 받기
21.05
0.34%
0.015
전일 마감가:
$21.03
열려 있는:
$21.12
하루 거래량:
659.18K
Relative Volume:
0.56
시가총액:
$2.57B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
17.83
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
-2.40%
1개월 성능:
-6.14%
6개월 성능:
-7.94%
1년 성능:
+24.56%
1일 변동 폭
$21.05
$21.42
1주일 범위
$20.60
$21.78
52주 변동 폭
$15.34
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.05 | 2.64B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.21 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.38 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.87 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
567.18 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.33 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
What drives Catalyst Pharmaceuticals Inc. stock priceHigh-octane financial growth - Autocar Professional
What analysts say about Catalyst Pharmaceuticals Inc. stockOverwhelming financial success - jammulinksnews.com
Is Catalyst Pharmaceuticals Inc. a good long term investmentLightning-fast growth - jammulinksnews.com
Catalyst Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit margins - jammulinksnews.com
Why Catalyst Pharmaceuticals Inc. stock is on top investor watchlistsSafe and Smart Investment Picks - Newser
Published on: 2025-07-17 22:44:23 - Newser
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo.co
Teacher Retirement System of Texas Sells 2,766 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyFree Stock Tips Group - beatles.ru
Why Catalyst Pharmaceuticals Inc. stock attracts strong analyst attentionPro Trader Stock Focus - Newser
How Catalyst Pharmaceuticals Inc. stock performs during market volatilityRisk Aware High Growth Picks - Newser
Principal Financial Group Inc. Purchases 17,018 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Amalgamated Bank Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Cambridge Investment Research Advisors Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
GAMMA Investing LLC Acquires 579 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Institutional investors in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) lost 3.5% last week but have reaped the benefits of longer-term growth - simplywall.st
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by New York State Teachers Retirement System - Defense World
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 244,148 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals is Now Oversold (CPRX) - Nasdaq
Top 3 Health Care Stocks You'll Regret Missing This Quarter - inkl
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Nasdaq
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Reports Strong Q1 2025 Earnings Growth - Yahoo Finance
Stanley Laman Group Ltd. Acquires New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
GAMMA Investing LLC Has $1.64 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 5.2% Following Insider Selling - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $42,272.00 in Stock - MarketBeat
Trading (CPRX) With Integrated Risk Controls - news.stocktradersdaily.com
Preethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals Stock - Nasdaq
Insider Sell: Preethi Sundaram Sells Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus
Preethi Sundaram Sells 2,324 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
117,374 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Bridge City Capital LLC - MarketBeat
Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock - Nasdaq
Strong Inflows Make Catalyst Stock an Outlier - FXEmpire
Insider Sell: Patrick Mcenany Sells 200,000 Shares of Catalyst P - GuruFocus
Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals stock soars to all-time high of $26.49 - Investing.com Australia
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.17%
자본화:
|
볼륨(24시간):